... Evaluación de la seguridad y efectividad del CIMAher® (Nimotuzumab) en el tratamiento de pacientes con adenocarcinoma de páncreas ... claves:  Nimotuzumab, cáncer de páncreas localmente avanzado, irresecable, ...

Ensayos Clínicos - CIM - 30/07/2019 - 2:43pm

... Title:  Nimotuzumab in NSCLC Scientific title:  ... histology NSCLC, treated with concurrent CT-RT plus Nimotuzumab vs concurrent CT-RT. Acronym of ...

Clinical Trials - CIM - 28/12/2018 - 11:16am

... Nimotuzumab en CPCNP Título completo del ... III inoperables, tratados con QT-RT concurrente más Nimotuzumab vs QT-RT concurrente. Siglas ... Nimotuzumab en CPCNP concomitante con QRT ...

Ensayos Clínicos - CIM - 28/12/2018 - 11:15am

... Efficacy and safety of cold kit of monoclonal antibody nimotuzumab labeled with 99mTc for the immunodiagnosis of head and neck tumors, ... Group I- MAb Nimotuzumab 3mg (Experimental). Immunoscintigraphy with the ...

Clinical Trials - CIM - 05/10/2018 - 8:50am

... y seguridad del kit frío del anticuerpo monoclonal nimotuzumab marcado con 99mTc para el inmunodiagnóstico de tumores de cabeza y ... claves:  Nimotuzumab, cabeza y cuello, pulmón, gliomas ...

Ensayos Clínicos - CIM - 05/10/2018 - 8:49am

... F., Reuter D, Edler L., and Mross K. Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor ... et al. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with ...

Ensayos Clínicos - CATALYSIS - 01/08/2018 - 9:04am

... preparation NGcGM3/VSSP and the monoclonal antibody nimotuzumab, in patients with advanced non-small cell lung cancer (NSCLC) ... to 24 months Group B (patients with + EGF-R expression) nimotuzumab AcM (intravenous) : 200 mg, the first 6 doses every 7 days, and the ...

Clinical Trials - CIM - 30/04/2018 - 3:00pm

... preparado vacunal NGcGM3/VSSP y el anticuerpo monoclonal nimotuzumab, en pacientes con cáncer avanzado de pulmón de células no ... 24 meses Grupo B (pacientes con expresión + EGF-R): AcM nimotuzumab (intravenoso) : 200 mg, las primeras 6 doses cada 7 días, y el ...

Ensayos Clínicos - CIM - 30/04/2018 - 2:59pm

... Evaluation of the safety and effectiveness of CIMAher® (Nimotuzumab) in the treatment of patients with locally advanced adenocarcinoma ... Group I (experimental): 2 year treatment with Nimotuzumab 400 mg once a week (intravenous) until discontinuation criteria, in ...

Clinical Trials - CIM - 30/04/2017 - 4:09pm

... Use of monoclonal antibody Nimotuzumab and radio-chemotherapy in the treatment of patients with locally ... Experimental group: RadioChemotherapy + Anti-EGFR mAb Nimotuzumab at 200 mg intravenously. The Nimotuzumab will have an induction ...

Clinical Trials - CIM - 17/02/2017 - 4:24pm